A Study to Learn About Study Medicine Called PF-07261271 in Healthy People
Launched by PFIZER · Sep 7, 2022
Trial Information
Current as of June 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy individuals as determined by medical evaluation
- • Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb).
- Exclusion Criteria:
- • Clinically significant medical conditions
- • History of HIV infection, hepatitis B, or hepatitis C
- • BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic)
- • Clinically relevant ECG abnormalities
- • Previous study drug administration within 30 days or 5 half-lives of first planned dose
- • History of drug/alcohol abuse or \>20 cigarettes/day
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tustin, California, United States
Salt Lake City, Utah, United States
Eatontown, New Jersey, United States
Salt Lake City, Utah, United States
Lake Forest, California, United States
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials